+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Oral contraceptive use and fibrocystic breast disease among pre- and postmenopausal women

Oral contraceptive use and fibrocystic breast disease among pre- and postmenopausal women

American Journal of Epidemiology 120(1): 87-96

The association between oral contraceptive (OC) use and fibrocystic breast disease was assessed among women ages 20-74 in a hospital-based case-control study conducted between November 1979-November 1981 in Connecticut. The study groups comprised 633 women with biopsy-proven fibrocystic disease and 1062 controls who had been admitted as inpatients or outpatients to general surgical services. For the premenopausal women, there was no evidence that longterm OC use was associated with a decreased frequency of fibrocystic breast disease among either current or past users. For the postmenopausal women, previous OC exposure was associated with an increased occurrence of cyctic disease. These findings contradict previous investigations which reported a negative association between OC use and the development of fibrocystic breast disease.

(PDF emailed within 1 workday: $29.90)

Accession: 043844977

Download citation: RISBibTeXText

PMID: 6741927

Related references

Fibrocystic disease in women receiving oral contraceptive hormones. Cancer 25(6): 1332-1339, 1970

Oral contraceptive use and fibrocystic breast disease of different histologic classifications. Journal of the National Cancer Institute 72(2): 285-290, 1984

From the NIH: Oral contraceptive use no protection against cancer risk-associated fibrocystic breast disease. JAMA 241(1): 24-24, 1979

Oral contraceptive use and fibrocystic breast disease with special reference to its histopathology. Journal of the National Cancer Institute 71(1): 5-9, 1983

Estrogen replacement therapy and fibrocystic breast disease in postmenopausal women. American Journal of Epidemiology 121(2): 238-245, 1985

Fibrocystic breast disease in oral-contraceptive users. A histopathological evaluation of epithelial atypia. New England Journal of Medicine 299(8): 381-385, 1978

Hormone therapy: three perspectives. Fibrocystic breast disease: contraindication for oral contraceptive therapy. Journal of Nurse-Midwifery 25(2): 15-16, 1980

Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes & Control 16(5): 537-544, 2005

Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women. Cancer Causes & Control 14(10): 933-943, 2004

Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Fertility and Sterility 85(5): 1425-1431, 2006

Oral contraceptive use and the risk of breast cancer in women with a "prior" history of benign breast disease. American Journal of Epidemiology 123(3): 373-382, 1986

A randomized trial of oral contraceptive and hormone replacement therapy on bone mineral density and coronary heart disease risk factors in postmenopausal women. Obstetrics & Gynecology 95(1): 87-94, 2000

Critical, morphological, and histopathogenic considerations on fibrocystic breast disease; fibrocystic disease and carcinoma of the breast. Archivio Italiano di Anatomia E Istologia Patologica 24(6): 473-514, 1951

Oral contraceptive use and risk of benign breast disease in a French case-control study of young women. European Journal of Cancer Prevention 2(2): 147-154, 1993

Anovulation and increased androgenic activity as breast cancer risk in women with fibrocystic disease of the breast. Cancer Research 38(9): 3051-3054, 1978